Your Immune System Ages Too - What the 2026 Urolithin A Trial Actually Shows

Most people who've discovered Urolithin A know it as the muscle supplement. The research on mitochondrial health and physical performance is hard to argue with — a 2022 randomised trial found roughly a 12% improvement in muscle strength, backed by measurable reductions in inflammation and direct evidence of upregulated mitophagy in skeletal muscle biopsies (Singh et al., 2022, Cell Reports Medicine).

But a study published in Nature Aging in early 2026 opened a different door entirely. The finding isn't about your muscles. It's about your immune system — and why that distinction matters more the older you get.

The Study That Changed the Picture

The 2026 RCT by Denk et al., published in Nature Aging, enrolled 50 adults between the ages of 45 and 70. Participants took 1,000 mg of Urolithin A daily for 28 days. Researchers tracked cellular immune markers before and after.

The headline finding: naïve CD8+ T-cells — the "young, responsive" immune cells your body recruits to fight new threats — expanded significantly. At the same time, markers of T-cell exhaustion declined. The immune profile, in measurable ways, became more similar to that of a younger person.

Why does this matter? As we age, the proportion of naïve CD8+ T-cells shrinks and is replaced by exhausted or highly differentiated cells that are less able to respond effectively to novel pathogens, vaccines, or abnormal cells. This isn't just an abstract biological observation — it's one of the mechanisms behind why infections, some cancers, and vaccine efficacy gaps tend to cluster in older adults.

(Source: AliveLongevity.com citing Denk et al., Nat Aging. 2025 Nov 31;5(11):2309–22.)

Why Urolithin A Affects the Immune System at All

The mechanism runs through mitochondria - specifically, through a cellular clean-up process called mitophagy. Damaged or dysfunctional mitochondria accumulate in immune cells just as they do in muscle cells. When those mitochondria aren't cleared efficiently, immune cell metabolism degrades and exhaustion accelerates.

Urolithin A activates the mitophagy pathway. In doing so, it doesn't just support muscle fibres - it supports every cell type that relies on healthy mitochondria, and immune cells are energy-intensive enough to notice the difference.

A 2024 systematic review of five RCTs involving 250 individuals found consistent dose-dependent anti-inflammatory effects, increased muscle strength and endurance, and upregulation of mitochondrial and autophagy genes.

The Gut Conversion Problem

Here's a complication most content about Urolithin A glosses over: the compound isn't found directly in food. It's produced in the gut when specific bacteria metabolise ellagitannins from pomegranates, walnuts, and certain berries.

Only 40–60% of people have the gut microbiome composition needed to produce meaningful amounts of Urolithin A this way. A liposomal delivery format bypasses this bottleneck entirely.

What the Muscle Evidence Adds

The Singh et al. 2022 RCT (Cell Reports Medicine, PMID 35584623) demonstrated approximately a 12% improvement in muscle strength, significant reductions in plasma acylcarnitines and C-reactive protein, and direct upregulation of mitophagy proteins in skeletal muscle biopsy samples.

A 2022 trial in JAMA Network Open replicated the endurance and mitochondrial health findings in adults aged 65–90.

Who Should Actually Care About the 2026 Immune Trial

The trial recruited adults aged 45–70. Immune ageing doesn't begin at 65. It starts in your 40s, accelerates through your 50s, and compounds quietly until it shows up as something harder to ignore.

A March 2026 paper in npj Aging found that early Urolithin A activation prevents age-related cognitive decline in the hippocampus - but does not reverse decline once it's established.

Our Urolithin-A Liposomal is formulated for maximal absorption without relying on gut conversion. Each serving delivers 1,000 mg UA in a liposomal phospholipid matrix, the same dose used in the 2026 Nature Aging immune trial.